关键信息
-
基因名
HER2/CD340
- 应用
-
别名
Receptor tyrosine-protein kinase erbB-2; MLN 19; CD340; ERBB2; HER2; NEU; NGL
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-Avi;C-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P70424
-
表达区间
T23-T653
-
分子量
110-130 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HER2, also known as CD340, is a member of the human epidermal growth factor receptor (HER/EGFR) family and plays a crucial role in cell growth, differentiation, and survival. Overexpression of HER2 is associated with aggressive forms of breast cancer and has been linked to poor prognosis, making it a significant target for therapeutic intervention. Research into HER2/CD340 recombinant proteins is primarily driven by the need for targeted therapies, such as monoclonal antibodies and small molecule inhibitors, that can specifically disrupt the signaling pathways activated by HER2 overexpression. These recombinant proteins can be utilized in various applications, including the development of diagnostic tools to identify HER2-positive tumors and the creation of novel therapeutic agents like antibody-drug conjugates that deliver cytotoxic drugs directly to cancer cells. Furthermore, understanding the structure and function of HER2/CD340 at the molecular level facilitates the design of more effective inhibitors and enhances the potential for personalized medicine approaches. Rigorous studies on HER2/CD340 recombinant proteins continue to provide insights into its mechanics and role in oncogenesis, paving the way for innovative strategies to combat HER2-positive cancers and ultimately improve patient outcomes.
